What commercial milestones did Control Bionics (ASX:CBL) announce in its latest market update?

Control Bionics announced international expansion and pipeline advancement across its three core neurotechnology platforms. Key milestones include securing a nationwide US insurance billing model, gaining insurance coverage in Germany, signing a large product letter of intent, and advancing clinical validations for its wearable technology.

How is Control Bionics (ASX:CBL) expanding its footprint in the US market?

The company established a nationwide US insurance billing model following the allocation of the E2513 HCPCS billing code. This regulatory milestone directly enabled Control Bionics to execute major nationwide distribution partnerships with Tobii Dynavox and PRC-Saltillo.

What international insurance coverage did Control Bionics (ASX:CBL) secure outside the US?

Control Bionics secured a funded market pathway in Europe by obtaining HMV insurance coverage in Germany. This milestone allows for structured reimbursement, making its neurotechnology platforms more accessible in the German healthcare ecosystem.

What are the details of the NextLevel device agreement signed by Control Bionics (ASX:CBL)?

Control Bionics signed a letter of intent for 1,000 NextLevel iOS-based communication devices, securing a US$100,000 upfront payment. This agreement supports a partner-led distribution model aimed at accelerating the company's product expansion.

When is the Control Bionics (ASX:CBL) Apple BCI integration expected to launch?

The anticipated Apple Brain-Computer Interface (BCI) integration is currently in development by Control Bionics. Management has targeted a global release for the product in Q3 2026.

Tech

Image for illustrative purposes only. Not a real photo.

Control Bionics drives global neurotech expansion

Q: What is NeuroStrip, and who is currently evaluating it?

NeuroStrip is a wearable surface electromyography (sEMG) platform developed by the NeuroTech Solutions division of Control Bionics. Structured evaluation programmes are currently underway with elite sporting organisations like the AFL, NRL, and the Australian Institute of Sport, alongside clinical institutions such as Ohio University.

Written by Brie CarterPublished Jun. 4 2026Last Updated Jun. 4 2026

Medical technology company Control Bionics (ASX:CBL) announced commercial momentum and pipeline advancement across its three core neurotechnology platforms: Assistive Technology, Neurotechnology Solutions, and Medical Technology.

The company has expanded its global footprint through pivotal international distribution agreements and insurance reimbursement milestones.

A major driver of this growth is the establishment of a nationwide US insurance billing model following the allocation of the E2513 HCPCS billing code, which enabled January distribution partnerships with Tobii Dynavox and PRC-Saltillo.

Control Bionics also secured a funded market pathway in Europe after obtaining HMV insurance coverage in Germany this past February.

Further accelerating product expansion, the company signed an April 2026 letter of intent for 1,000 NextLevel iOS-based communication devices, securing a US$100,000 upfront payment to support a partner-led distribution model.

Additionally, an anticipated Apple BCI integration is currently in development, with a global release targeted for Q3 2026.

The NeuroTech Solutions division is advancing commercial validation for NeuroStrip, its wearable sEMG platform.

Structured evaluation programmes are currently underway with prestigious clinical institutions and elite sporting organisations, including the AFL, NRL, Australian Institute of Sport, and Ohio University.

A recent Japanese Stroke Lab study demonstrated a 39% reduction in muscle overactivity using the NeuroStrip application.